Philip Law

Philip Law

Auto-generated profile, based on publicly available information

Philip Law

Division of Genetics and Epidemiology, The Institute of Cancer Research, London, UK

Research Focus & Metrics

Academic Career Length

19Years (2008-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
20 December 2022 in Nature Genetics
Verified
Journal Article
Closed access
PDF file
Ceres Fernández-RozadillaCeres Fernández-Rozadilla
Ceres Fernández-Rozadilla
MTMaria Timofeeva
Maria Timofeeva
ZCZhishan Chen
Zhishan Chen
PLPhilip Law
Philip Law
MTMinta Thomas
Minta Thomas
UPUlrike Peters
Ulrike Peters

14 May 2019 in Nature Communications
Verified
Journal Article
Open access
PDF file
PLPhilip J. Law
Philip J. Law
MTMaria Timofeeva
Maria Timofeeva
Ceres Fernández-RozadillaCeres Fernández-Rozadilla
Ceres Fernández-Rozadilla
PBPeter Broderick
Peter Broderick
JSJames Studd
James Studd
MDMalcolm G. Dunlop
Malcolm G. Dunlop
Colorectal cancer (CRC) is a leading cause of cancer-related death worldwide, and has a strong heritable basis. We report a genome-wide association analysis of 34,627 CRC cases and 71,379 controls of European ancestry that identifies SNPs at 31 new CRC risk loci. We also identify eight independent risk SNPs at the new and previously reported European CRC loci, and a further nine CRC SNPs at loci previously only identified in Asian populations. We use in situ promoter capture Hi-C (CHi-C), gene expression, and in silico annotation methods to identify likely target genes of CRC SNPs. Whilst these new SNP associations implicate target genes that are enriched for known CRC pathways such as Wnt and BMP, they also highlight novel pathways with no prior links to colorectal tumourigenesis. These findings provide further insight into CRC susceptibility and enhance the prospects of applying genetic risk scores to personalised screening and prevention.

7 August 2024 in Nature
Verified
Journal Article
Open access
PDF file
ACAlex J. Cornish
Alex J. Cornish
AGAndreas Gruber
Andreas Gruber
BKBen Kinnersley
Ben Kinnersley
DCDaniel Chubb
Daniel Chubb
AFAnna Frangou
Anna Frangou
Richard HoulstonRichard Houlston
Richard Houlston
Colorectal carcinoma (CRC) is a common cause of mortality1, but a comprehensive description of its genomic landscape is lacking2–9. Here we perform whole-genome sequencing of 2,023 CRC samples from participants in the UK 100,000 Genomes Project, thereby providing a highly detailed somatic mutational landscape of this cancer. Integrated analyses identify more than 250 putative CRC driver genes, many not previously implicated in CRC or other cancers, including several recurrent changes outside the coding genome. We extend the molecular pathways involved in CRC development, define four new common subgroups of microsatellite-stable CRC based on genomic features and show that these groups have independent prognostic associations. We also characterize several rare molecular CRC subgroups, some with potential clinical relevance, including cancers with both microsatellite and chromosomal instability. We demonstrate a spectrum of mutational profiles across the colorectum, which reflect aetiological differences. These include the role of Escherichiacolipks+ colibactin in rectal cancers10 and the importance of the SBS93 signature11–13, which suggests that diet or smoking is a risk factor. Immune-escape driver mutations14 are near-ubiquitous in hypermutant tumours and occur in about half of microsatellite-stable CRCs, often in the form of HLA copy number changes. Many driver mutations are actionable, including those associated with rare subgroups (for example, BRCA1 and IDH1), highlighting the role of whole-genome sequencing in optimizing patient care.

12 June 2017 in Nature Genetics
Verified
Journal Article
Open access
PDF file
UCUK Testicular Cancer Collaboration
UK Testicular Cancer Collaboration
KLKevin Litchfield
Kevin Litchfield
TCThe PRACTICAL Consortium
The PRACTICAL Consortium
MLMax Levy
Max Levy
GOGiulia Orlando
Giulia Orlando
CTClare Turnbull
Clare Turnbull
Clare Turnbull and colleagues report discovery of 19 new susceptibility loci for testicular germ cell tumor (TGCT) and provide evidence for a network of physical interactions between TGCT risk variants and candidate causal genes. Their findings implicate widespread disruption of developmental transcriptional regulators in TGCT susceptibility, consistent with failed primordial germ cell differentiation as an initiating step in oncogenesis. Genome-wide association studies (GWAS) have transformed understanding of susceptibility to testicular germ cell tumors (TGCTs), but much of the heritability remains unexplained. Here we report a new GWAS, a meta-analysis with previous GWAS and a replication series, totaling 7,319 TGCT cases and 23,082 controls. We identify 19 new TGCT risk loci, roughly doubling the number of known TGCT risk loci to 44. By performing in situ Hi-C in TGCT cells, we provide evidence for a network of physical interactions among all 44 TGCT risk SNPs and candidate causal genes. Our findings implicate widespread disruption of developmental transcriptional regulators as a basis of TGCT susceptibility, consistent with failed primordial germ cell differentiation as an initiating step in oncogenesis1. Defective microtubule assembly and dysregulation of KIT–MAPK signaling also feature as recurrently disrupted pathways. Our findings support a polygenic model of risk and provide insight into the biological basis of TGCT.

13 September 2018 in Nature Communications
Verified
Journal Article
Open access
PDF file
MWMolly Went
Molly Went
ASAmit Sud
Amit Sud
AFAsta Försti
Asta Försti
BHBritt-Marie Halvarsson
Britt-Marie Halvarsson
NWNiels Weinhold
Niels Weinhold
STStephen N. Thibodeau
Stephen N. Thibodeau
Genome-wide association studies (GWAS) have transformed our understanding of susceptibility to multiple myeloma (MM), but much of the heritability remains unexplained. We report a new GWAS, a meta-analysis with previous GWAS and a replication series, totalling 9974 MM cases and 247,556 controls of European ancestry. Collectively, these data provide evidence for six new MM risk loci, bringing the total number to 23. Integration of information from gene expression, epigenetic profiling and in situ Hi-C data for the 23 risk loci implicate disruption of developmental transcriptional regulators as a basis of MM susceptibility, compatible with altered B-cell differentiation as a key mechanism. Dysregulation of autophagy/apoptosis and cell cycle signalling feature as recurrently perturbed pathways. Our findings provide further insight into the biological basis of MM.

1 October 2017 in European Journal of Cancer
Verified
Journal Article
Open access
SMSebastian May-Wilson
Sebastian May-Wilson
ASAmit Sud
Amit Sud
PLPhilip J. Law
Philip J. Law
KPKimmo Palin
Kimmo Palin
STSari Tuupanen
Sari Tuupanen
Richard HoulstonRichard Houlston
Richard Houlston
While dietary fat has been established as a risk factor for colorectal cancer (CRC), associations between fatty acids (FAs) and CRC have been inconsistent. Using Mendelian randomisation (MR), we sought to evaluate associations between polyunsaturated (PUFA), monounsaturated (MUFA) and saturated FAs (SFAs) and CRC risk. We analysed genotype data on 9254 CRC cases and 18,386 controls of European ancestry. Externally weighted polygenic risk scores were generated and used to evaluate associations with CRC per one standard deviation increase in genetically defined plasma FA levels. Risk reduction was observed for oleic and palmitoleic MUFAs (OROA = 0.77, 95% CI: 0.65-0.92, P = 3.9 × 10-3; ORPOA = 0.36, 95% CI: 0.15-0.84, P = 0.018). PUFAs linoleic and arachidonic acid had negative and positive associations with CRC respectively (ORLA = 0.95, 95% CI: 0.93-0.98, P = 3.7 × 10-4; ORAA = 1.05, 95% CI: 1.02-1.07, P = 1.7 × 10-4). The SFA stearic acid was associated with increased CRC risk (ORSA = 1.17, 95% CI: 1.01-1.35, P = 0.041). Results from our analysis are broadly consistent with a pro-inflammatory FA profile having a detrimental effect in terms of CRC risk.